Thank R&D go strategy. you, we'll and to Today's will Robert. cover financials, Then manufacturing and and Q&A. facility Elite's distribution commercial sales update pipeline,
Elite's I'll fundamental manufacturing with that and distribution and R&D sound financials. sheet strong start sales to leads a with systems a balance pipeline, organization. few Good start a words about
pleased This are cash for quarter the one. with task. and the numbers and fourth very of with start that direction had year-to-year. growth taking I'll first to is going profitability. Elite I revenues, our am and for looking Elite year on flow sales the the profits So and both solid forward
enough we ago, for self-sufficient to capital. are not long Not did money profitable. we Today, pay have working and
is easy fourth and target a annual this for That row. task common nor have performance it's revenues last the exceed and on not year quarter are for an we OTC an We in year-to-date, surpass company. to year's solid for and revenues
past Elite our a us revenues a have and It pipeline. stockholders. that unfortunate in met four and employees is opportunity decline by the positive a profitability XXX% frustrating the the note, more in gave price. years, to R&D It me, increase our of was Board Directors, On revenues over the with to strong increase XX% share in is than the
continues to Elite in development. invest product
takes grow diversify solid our products and portfolio. Our on commercialize build pipeline. continue system is to goal It years R&D to new to to a competitive
product need an easy you selection, task. First, not
It involves because market China competitive of who's now. to you years in to to or never us. more pricing own they're who manufacture than from going uncertainty the going API is are and And a several going in in know be India whether lot where they the plant
selection many CapEx your Then facility to to fluid with those or such made investment, that substances products cannot on Elite fluid-bed as pre-formulation involve products to major example, a where your involve technology facility. be you can you advantage move of selected make blood how could -- remodify capital difficult-to-make these at an be formulations analyze the without overseas. area an that controlled governed for has the because, This
you So at eliminate least part that the competition. of
Then optimization. going through formulation the
brand, what distribution. do filing, can inspections, an every so stability, FDA again, which these R&D of create of to approval manufacturing mentioned this and challenging pivotal scale you a because AMDA larger of clinical steps one and entire the long-term clinical system money, the R&D pilot takes in is to vitro cost We it profile, also lots a of lot money, I and have trials, formulations, an comparison pipeline. and each finally, stability, impurity to have trials, time and optimization sales
have the that of input been of better And now picking Several sales selection. future. we chance have with and the in best the making products selected. evaluated a marketing, opportunity product money have and First, at products the
step stage. development products entered into is Second other the formulation
is help formulation with the first part have second is of now is into the trials. are clinical and viable And analysis and a team filled potential as not. that pipeline the go So what second, of analysis done getting for to products what's screened and the the Kirko being we being
evaluation into Several comparison. had vitro products Elite two have or formulation additional clinical this the this development phase year And from and that are study has undergoing quarter. phase in moved the products brand
an recently Elite and product studies And and made as is to that we both, extended be a opioid has we in filed well. has year that on filed successful about this an We've there press filed will are for updated working be It's completed have is before. that AMD on you been other release QX. been and the third expected two a one that study, releases issued insufflation have announcement generics. on generic BE filed doing
So have now pipeline true each stages we if every development, of one years populated come. of a from them for at to product the you be look all and to several continuing to have that us will
a development approval. on BE other we as you filing study, We products when specific milestones the reach will such or update
distribution. us sales sheet balance healthy but and a manufacturing Now also to also support and R&D, enabled
We improve and our facility equipment to new by continue adding manufacturing personnel.
have two pillar look Again, the enhanced the maintain to shift, for one is except packaging, we business are that We with where able third this I for. current shifts.
a to stage, now have sheet. balance the expand one every two sound an capable R&D you we have sure the or make that do demand capacity. it an are And facility, Then have go we with have do even enhanced, shifts to as equipment is throughout shift manufacturing the equipment pipeline the but First, weekend. redundant do at We're that, is running three granted and can to some potentially that we to to have and we populated comes. we that personnel
supporting the it is one our was today, it of capable Lannett. at As under as are running partner, of shift, we business and as
products and sales not This now. organization. to Lannett division about FDA. distribution this did year we learned have a is the a their that own for you we and approved Next, before since about as talked by I've that had got that Ever
a getting and stuff. of started sales bringing working and marketing and that We all on professional licenses
now. So right this said what we is
organization. are with have sales our now label We and for own own launch been to and ready our distribution preparing
sales large has product strategic the last and controlled of both our with share and in for place and of control wholesale warehousing XX retain contracts and products and key of to Direct more pricing a in revenues strategy. Elite's Compendia manufacturing that important give with in step discussion, reporting District logistics, profits place Elite listed Elite substances and all for Since has are allows are product and the to distributors Columbia. sales ], sales are us an [ direct follow. others certain states financial non-controlled licenses the products. us
a following products DEA market. Elite management the market have in in Amphetamine competitive quota been has April, ER. The labs and of label. IR and These can are our products in the elite challenging. will Starting be under
ER remain interested Elite's them in remains to supplier products both supplying IR and on do the list under do until FDA very and those continue after we'll well continue take We're Amphetamine label. over, for to very the going expect to Elite's label. shortage customers well I April. And very Lannett expects that, IR products. Elite quality and to under
April. of trumapramine Isradipine be Elite's label will as as and under sold well
products competitors, be of both Loxapine size, in only and have believe modest being two will Dantrolene products. help Elite also directly under that involved these one Elite's offered can We margins the the will be Although attractive. of to pricing X as and April or therefore, value in label. increase
with Loxapine challenging list. [indiscernible]. has recently Dantrolene pricing product the FDA's been the competitors has like on shortage been
We we are margins capture a share good label. under own with expecting, enter market though, modest our as to
select addition, to sell through we continue licensees. products In
opportunities of outside to long-term provide reaching U.S., couple very we forward of of partners. International updates going with Our that. develop work products will sales has or Elite of partner milestones our material sales. a least but opportunities continue levels example slowly, of upon at study and is for an the which moving
market product specialty of approval, its the and a and time The we very challenging specific Elite an filed got because other became when so Vigabatrin is in acquiring product so companies the -- a the the get more in difficult competitive market. and sell. it at to time is because many
to received, job money So addition contract to this kind a we have this in is of for divest how decided suited who with product. to more three-year also we buyers. that knows manufacturing it with And partner handle this -- buyer to
another distribution executing exciting We on and up, To good our plan look an forward growth wrap its to own Elite department. and year. quarter is and sales launching
the Q&A about before to Dianne. questions me start a to with Q&A go we and comment you Let submitted little
or are intelligent. pretty time comments are and on the -- little a some advice. outburst always this questions and were are more the of emotional Some Others predictions
couple what give And I we'll them get. we'll usually answer is the business. a that really on do examples relevant the is and group So I'll things to of what
money that. We we the were Isn't of people have there. the stock Lots is the perfect have So time stock about be buyback? things, this on of strategy the asked okay? couple depressed The other did not group, a a stock and declare priorities a a advice first committed buyback. different it could if to for
products and have be to you and to worrying after your sales do. When spare we the money. marketing, R&D new extra about and a thing This extra own have wouldn't developing loan and bad supporting money
that in We a not are position right to do now.
the voice, but back money about borrow for it we half has your time. these you not think if the to. all Buy things the for same don't answer. Again, shares, outstanding company Thank are
What Again, never product. to we've a plans talked making a does have nongenetic nongeneric Elite product? produce about
or We and knows is status other generic. have everybody technology, what SequestOx all of are the the products and
So discussing from. sure. we'll be I'm not
many an pending And you of don't have for on can we do the we time most simply that's products, those people is We data that drugs. and of revenues how trials for Update not potential by because we in. generics, know new get future tell comment IMS the future approval, is. gotten question, what revenues
now before impossible. approval or people are we you much many so to make to know we're have there is So tell going even how there's we
But earlier, spoke the opioid, of I as that I BE, other one go that three into to clinical and trials your the question, will filed two about, coming have is product soon, we within already will right first now filed quarters. products one other the has and that's as the be part stated two
Okay.
Several SequestOx. about questions
now, The know or fees. and the allow pull and on support we pending not. trials, decided of is a will with as we to finally clinical first on in if you let move SequestOx we're you rest plug That's the final a life It's the funny. application is still
SequestOx does abused really they considered its abuse a be that. competitors, is actually. against Remoxy RoxyBond. and Remoxy the to physical current smart That's technology up How that's question, a struggled and with
was three them their really too. which They morphine filings rejected the They've FDA for is did which RoxyBond, give was is not good and made struggling ones a sulfate. company rejected three with makes times. that FDA, three got Morphabond, And the the the multiple they took is And second before of -- took has good. It opioids. been up, times technology one NDA which
the the Oxy This cost dollars, They one to products. they have products, of of -- have of so well. these and is revenues be millions tens done Oxycodone. branded both were And than products cost very detailed, are less
a So they were few from next. sold I ago, we to these products been now one years to know the offered company have up us. ended because
but that the is they of fact The best is still Elite's would encounter technology with challenges are the cost. them, all encountering same of we
are out With we of these All our products to we have VA generics. even there, products everybody the to for talks they these in the and at get the respect SequestOx, the if extremely the products. don't figure and buy once market in And crisis for the the to because with government U.S. the they're IR and OxyIR inexpensive. do need what time and opioids, IR about
VA the people, insurance insists They now. their of it. and not further more are dollar example, buying still for them generic on are the goes They because covering their buying or
we the not But if don't have multiple because that way penetrate product More to now. was they haven't better for ERs that us leak we have ours reasons. more technology market lucrative is the -- about I have, SequestOx would So the the than used me though about think is it better and found be, same one because to. the is sounds product question that ER the really a even for market sexy, except a Pfizer I always like right to
for rounding sheet launch. for risk balance saw our yet got they launch. and error Elite but they a entire approval And a they did and not are not and They revenues [indiscernible], did Pfizer's
would I with to figure for what that would be do I not about think and out future, the two. product other it, the So the
please Operations, provide can on question. you That's an situation? good a update the net
numbers, done expectation is the because Lannett quarter. be Lannett, contract would that Our quarter, and my are well X of from it. we're do the we making, okay? we is last selling dip with and are the of you the quarter to we've well is dip taking We to April all after saw own transitioning almost a process have marketing It they and in this going date, split it may the team. we're products as The from the our done. sales
But in not for somebody So we be to April, to so own else. extra product and quota, give materials, order make we to June, our for past DA in May, for but you concurrently the will inventory you need launch, order doing the us time build you be would able can launch quarter. for in that EA the
that. successful do We them have not been letting at
of we going bit very that My that, we to well. coming may prediction to year, year going have this a okay? little the do dip. after than bigger be a So current But are is is
am the frankly, we'll hit we'll and million I year. -- next go for beyond, $XX hoping
Just a little bit more [ph]. pressure on care
have a Elite Monday-through of that a second little as we some enhanced It's Does the January, except as people for and shift. in packaging a late We in early little one stay only packaging? of second shift, Friday. needed, only come shift end started for run
Mr. about on VP from by Or point results and a you handle team. current distribution opportunities hiring new building see sales questions At and activities. first do Update and mainly any on employed of six months what a to his Kirko's Kirko. working shift Do a you the of Lots see being is Sales? provided Kirko infrastructure. of new he being new third
outstanding He's already of delivering not summarize my does, all He doing all will what too by is saying on he of okay? a expectations. at what and he to the and I that is the I've on all is be through that's is on. this, an all team. exceptional above, doing. and contracts of our details. the new sales that, you will of Well, addition updated go VP would working Kirko I Just states
have to an moved on week and in on Dallas. will of road I as for the in back burner together has stock many upward the at and entire Kirko Uplisting fashion. been sales not still meaningful the be NASDAQ sales the meeting is meetings these any a
my NASDAQ is always on the agenda. top of
We Let a do on things right. when not no will is so repeat. top of and to and happen the business agenda. NASDAQ need have anxious going time making we're running place price my have me low or anything split is when decisions. else. always to reverse in Uplisting get Emotions right. stock I'm
to because achievements low be may [ I We be with of patient. like stock divisions the the frustrated mentioned, have I doing X heck ] very all and well the in very so all price of to that just in. we're get not things mentioned a I But me we that is into wish that I and we're acknowledge that. rush stock being situation not through frustrating. going the that's make us
Poison We'll guess the Poison in will But selling, not read to a haven't open. keep renew going pertains about our concrete Pill, anything concrete Pill now, window, watch be or any and are people XXXX. to all and part lawsuit I seeing Elite. a to November options Short yet Elite there inquiring right it's it. of No. I We're is as it it.
Okay?
people the we damaged from naked not with chat who of not that the more and I Elite, the stockholders we short. really from or damage our price, stockholders that if some around then think are not hang they're stakeholders, for get years rooms stock happy our XX get past from are
company besides say appreciate runs he offered that. question question and help stock on Elite and about I Elite do to help. investors. more the your I marketing, gentleman can he What attract us to do propose goes what of more Elite the marketing promotion. Last the and can story do Can that to telling
we and okay, sales this is we R&D What we've profitable. the enhance stick is principles, knowledge to create us and and what have, manufacturing doing, on marketing do sheet like have, improve we focused system our stay did, like like can the the profits on fundamentals, develop revenues made job, been we pipeline organization what the balance
will we to then to move is be NASDAQ and move Now before NASDAQ, move that seriously when considered. NASDAQ or your to idea we
